Clinical trial
Treatment of Refractory Benign Esophageal Stricture by Endoscopic Injection of Adipose-derived Stem Cells and Stromal Vascular Fraction
NCT07913646 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment of Refractory Benign Esophageal Stricture by Endoscopic Injection of Adipose-derived Stem Cells and Stromal Vascular Fraction
- Lead sponsor
- Oslo University Hospital
- Phase
- Not applicable
- Overall status
- Enrolling by invitation
- Start date
- November 1, 2026
- Completion date
- December 31, 2027
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
esophageal stenosis acquired
Arms
As registered; 1 arm.
-
Intervention
Adipose derived stem cells and stromal vascular fraction will be injected in the benign esophageal stricture
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Resolution of dysphagia and esophageal stricture
Resolution of dysphagia defined as Mellow Pinkas score = 0 or an improvement of ≥ 2 points and esophageal luminal diameter ≥ 13 mm
Lead sponsor's other trials
Oslo University Hospital, most recent start first.
+828 more trials See the organization page
Similar trials
Same condition (Constriction, Pathologic) and phase, most recent start first.
+105 more trials See the condition page